In 2018, a taskforce organized by the National Institutes of Aging and the Alzheimer's Association (NIA‐AA) proposed a biomarker‐based diagnosis of AD based on the ATN classification system, which utilizes markers that reflect the main pathological hallmarks of AD: deposition of Aβ (Α), pathological Tau (T), and neurodegeneration (N).7 The gene discussed is MAPT; the disease is Alzheimer disease.